Affinity Bio Partners Launch Medical Cannabis Clinical Trials for Diabetic Nerve Pain in Pennsylvania

CannabisImage via Pixabay

CHESTER SPRINGS, PA — Affinity Bio Partners announced that it launched a clinical study in Pennsylvania for medical cannabis patients suffering from diabetic nerve pain.

According to, “A large American study estimated that 47% of patients with diabetes have some peripheral neuropathy.” Those who are enrolled in Pennsylvania’s medical cannabis program and suffer from diabetic nerve pain are urged to call 724-859-6200 or email [email protected] to check enrollment eligibility at no cost.

“I am so excited to be working on this clinical study with Dr. Bryan Doner and the Serena Group. The future of medical cannabis and cannabinoids as medical treatments are dependent upon properly performed clinical studies. It is time for companies to invest their money into performing clinical studies that prove safety and efficacy regarding their products,” says Christina DiArcangelo, CEO, Affinity Bio Partners.

For more information about Affinity Bio Partners, please visit

Thanks for visiting! Looking for some Chester County pride? We got you covered! Shop our MyChesCo store and show your love for Chester County, Pennsylvania. We got shirts, hats, and more – all with a unique ChesCo flair. Plus, proceeds from each purchase helps support our mission of bringing reliable information and resources to the people of Chester County.